ACTRN12616000012471尚未招募不适用
Safety and efficacy of ziv Aflibercept compounding in refractory diabetic macular oedema
Dr Andrew Riley0 个研究点目标入组 40 人开始时间: 2016年1月12日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria:
- •Ability to provide informed consent and complete study assessments
- •Age 18 years or older
- •Diabetic macular oedema not responding to compounded Avastin (Bevacizumab or ranibizumab)
- •Best corrected baseline visual acuity between 6/6 to 6/60 on ETDRS chart
- •Presence of sub retinal fluid or cystic intraretinal oedema on spectral domain OCT (SD-OCT) [Spectralis]
- •Documentation of the presence of sub retinal fluid or cystoid oedema less than 42 days since last treatment with an antiVegf agent.
排除标准
- •Recent CVA or MI
研究者
相似试验
已完成
1 期
The effect of zaltrap in the treatment of retinal retinal vascular disorders resistant to AvastiRetinal vascular disorders.Disorders of choroid and retinaH30-H36IRCT2015081723651N1Investigator17
终止
3 期
Efficacy and safety of intravitreal Ziv-aflibercept injection for the treatment of refractory diabetic macula edemaDiabetic macular edemaDiabetes mellitusDiabetic macular edemaOphthalmic complications of diabetes mellitusZiv-afliberceptBevacizumabintravitreal injectionanti-vascular endothelial growth factorsTCTR20191130001Faculty of Medicine, Khon Kaen University7
已完成
不适用
Investigation of clinical efficacy for Aflibercept in patients with polypoidal choroidal vasculopathy (PCV)Polypoidal Choroidal VasculopathyJPRN-UMIN000011091Department of Ophthalmology, Graduate School of Medical Sciences, Kyushu University50
尚未招募
不适用
Safety of ziv-aflibercept in retinal diseases in a Ghanaian population.Eye Diseasesdiabetic macula edema,PACTR201701001940111Imoro Zeba braimah20
招募中
3 期
The evaluation of efficacy of Favipiravir in patients with mild to moderate COVID-19IRCT20201005048936N1Dr. Abidi pharmacutical Co.126